(-0.22%) 5 011.12 points
(0.06%) 37 775 points
(-0.52%) 15 601 points
(2.68%) $84.95
(0.57%) $1.767
(1.02%) $2 422.50
(1.00%) $28.67
(-0.29%) $951.70
(0.29%) $0.942
(0.39%) $11.08
(0.31%) $0.806
(0.10%) $94.15
Live Chart Being Loaded With Signals
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics...
Stats | |
---|---|
Today's Volume | 99 900.00 |
Average Volume | 207 594 |
Market Cap | 2.05B |
EPS | HKD0 ( 2024-03-25 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -7.35 |
ATR14 | HKD0.0110 (0.58%) |
SinoMab BioScience Ltd Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
SinoMab BioScience Ltd Financials
Annual | 2022 |
Revenue: | HKD4.03M |
Gross Profit: | HKD4.03M (100.00 %) |
EPS: | HKD-0.290 |
Q2 | 2023 |
Revenue: | HKD8.47M |
Gross Profit: | HKD7.53M (88.87 %) |
EPS: | HKD-0.130 |
Q4 | 2022 |
Revenue: | HKD4.03M |
Gross Profit: | HKD4.03M (100.00 %) |
EPS: | HKD-0.140 |
Q2 | 2022 |
Revenue: | HKD7.46M |
Gross Profit: | HKD7.46M (100.00 %) |
EPS: | HKD-0.150 |
Financial Reports:
No articles found.
SinoMab BioScience Ltd
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, as well as in phase 1 clinical trial to treat multiple sclerosis, SLE, and NMOSD. Its products under the preclinical stage comprise SM17 for the treatment of asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06 to treat RA, SLE, NMOSD, and SS; SM09 for the treatment of NHL and RA; and TNF2 for the treatment of autoimmune diseases. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators